SuperworthTango Therapeutics revenue TNGX
Sales by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $53.8M
- Latest quarter, Q2 FY26
- $0
- −100% on a year earlier
- Fiscal year 2025
- $62.4M
- +48% on the year before
Tango Therapeutics' revenue was $53.8M over the twelve months to Jun 30, 2026, up 121% on a year earlier.
In its latest quarter, Q2 FY26, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $62.4M | +48% |
| FY2024 | $42.1M | +15% |
| FY2023 | $36.5M | +47% |
| FY2022 | $24.9M | −33% |
| FY2021 | $37M | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0 | −100% | $53.8M | |
| Q1 FY26 | $0 | −100% | $57M | |
| Q4 FY25 | $0 | −100% | $62.4M | |
| Q3 FY25 | $53.8M | +364% | $66.5M | |
| Q2 FY25 | $3.2M | −84% | $24.3M | |
| Q1 FY25 | $5.4M | −17% | $41M | |
| Q4 FY24 | $4.1M | −24% | $42.1M | |
| Q3 FY24 | $11.6M | +8% | $43.4M | |
| Q2 FY24 | $19.9M | +36% | $42.5M | |
| Q1 FY24 | $6.5M | +12% | $37.2M | |
| Q4 FY23 | $5.4M | −15% | $36.5M | |
| Q3 FY23 | $10.7M | +55% | $37.5M |
Against its peers
Companies in Drug Manufacturers - General nearest Tango Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| TNGXTango Therapeutics | $53.8M | +121% a year |
| ARQTArcutis Biotherapeutics | $464M | +76% a year |
| LQDALiquidia | $450.9M | |
| INDVIndivior Pharmaceuticals | $1.3B | +13% a year |
| OGNOrganon | $6.1B | −2% a year |
| NRIXNurix Therapeutics | $701.9M | |
| KNSAKiniksa Pharmaceuticals International | $840.8M | +59% a year |
| LGNDLigand Pharmaceuticals | $290.5M | +55% a year |
| AMRXAmneal Pharmaceuticals | $3.1B | +9% a year |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| ALKSAlkermes plc. | $1.7B | +11% a year |
| Peer median | $972.9M |
Where Tango Therapeutics ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Tango Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.